General practitioners are the first line to promote the human papillomavirus vaccine in teenagers and young female adults. The goal of this study is: to describe the perception, in France, of this vaccine by the general practitioners in the first 6 months after the publication of national recommendations and reimbursement of this vaccine by the Social security; to know the daily practice of the cervical cancer prevention. These questions were asked through a questionnaire sent to 545 general practitioners s in the Eure-et-Loir and Cher departments. We got 255 answers (46%); 73% have already use this vaccine, at least once, and 64% are ready to promote this immunization in girls over the age of 14.70% think the national recommendations can be applied without any negative impact on the cervical cancer screening by the cervical-smear because human papillomavirus vaccine do not eliminate the need of cervical cancer screening; 81% are motivated to justify this immunization in their patients even if 10% spontaneously mention the problem of the hepatitis B immunization in France as a limitation to implementation of a new vaccine. Although these results are encouraging, cervical cancer screening should be intensified and general practitioners, patients and their parents should get better information.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cervical cancer
20
general practitioners
20
cancer screening
12
cancer prevention
8
human papillomavirus
8
papillomavirus vaccine
8
national recommendations
8
general
6
vaccine
6
cervical
5

Similar Publications

Introduction: The core objective of this study was to precisely locate metastatic lymph nodes, identify potential areas in nasopharyngeal carcinoma patients that may not require radiotherapy, and propose a hypothesis for reduced target volume radiotherapy on the basis of these findings. Ultimately, we reassessed the differences in dosimetry of organs at risk (OARs) between reduced target volume (reduced CTV2) radiotherapy and standard radiotherapy.

Methods And Materials: A total of 209 patients participated in the study.

View Article and Find Full Text PDF

Background: Ovarian cancers (OC) and cervical cancers (CC) have poor survival rates. Tumor-infiltrating lymphocytes (TILs) play a pivotal role in prognosis, but shared immune mechanisms remain elusive.

Methods: We integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) to explore immune regulation in OC and CC, focusing on the PI3K/AKT pathway and FLT3 as key modulators.

View Article and Find Full Text PDF

An automatic cervical cell classification model based on improved DenseNet121.

Sci Rep

January 2025

Department of Biomedical Engineering, School of Life Science and Technology, Changchun University of Science and Technology, Changchun, 130022, China.

The cervical cell classification technique can determine the degree of cellular abnormality and pathological condition, which can help doctors to detect the risk of cervical cancer at an early stage and improve the cure and survival rates of cervical cancer patients. Addressing the issue of low accuracy in cervical cell classification, a deep convolutional neural network A2SDNet121 is proposed. A2SDNet121 takes DenseNet121 as the backbone network.

View Article and Find Full Text PDF

Objective: This study explored and compared stakeholder perspectives on enhancements to cervical cancer screening for vulnerable women across seven European countries.

Design: In a series of Collaborative User Boards, stakeholders were invited to collaborate on identifying facilitators to improve cervical cancer screening.

Setting: This study was part of the CBIG-SCREEN project which is funded by the European Union and targets disparities in cervical cancer screening for vulnerable women (www.

View Article and Find Full Text PDF

Background: Black women and other minorities have higher age adjusted incidence risk for cervical and endometrial cancer than White women. However, the extent of racial and ethnic disparities in clinical trial enrollment among studies performed mainly in North America and Europe for gynecologic malignancy is unknown.

Objective: This study analyzed enrollment rates by race/ethnicity in trials that led to Food and Drug Administration (FDA) approvals for gynecological cancers from 2010 to 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!